Correlation of Pfcrt, Pfmdr and PfK13 gene polymorphisms and in vitro drug susceptibility of Plasmodium falciparum isolates from China-Myanmar border region

doi:10.12140/j.issn.1000-7423.2020.05.009

Abstract

Abstract:

Objective To investigate correlation between the susceptibility to antimalarials and the polymorphisms of drug resistance genes of Plasmodium falciparum isolates from China-Myanmar border region, to provide basis for formulating rational strategy for using antimalarial drugs in the local areas. Methods In 2009, an investigation site was set up at the Nongriban Clinic in Lazan City, Myanmar, and the participant patients were selected based on the inclusion criteria: single infection of P. falciparum diagnosed by microscopy; and no chemotherapy history with antimalarials, sulfonamides, or tetracyclines within the past 2 weeks. For in vitro drug sensitivity test and genetic analysis, whole blood or filter paper blood samples were collected from the patients prior to drug treatment. The Rieckmann in vitro microassay method was used to assess the susceptibility of P. falciparum parasites to artemisinin, chloroquine, piperquine and pyronidine. Blood DNA was prepared to test examine the polymorphisms of chloroquine resistant transporter gene (Pfcrt), multiple-drug resistance (Pfmdr) and Kelch gene (PfK13). The associations between the susceptibility to antimalarial drugs and gene polymorphisms were analyzed with Spearman rank correlation coefficient test by SPSS 23.0 software. Results A total of 63 patients with single infection of P. falciparum examined by microscopy were included in this study, of them 51 samples underwent in vitro drug susceptibility test, with 42 samples were completed successfully, accounting for 82.4% (42/51). In the in vitro assay, P. falciparum showed higher mean inhibitory concentration, higher 50% inhibitory dose (ID₅₀) and higher resistance rate to chloroquine, which were 880 nmol/L, 320.5 nmol/L and 95.2%, respectively; and showed lower mean inhibitory concentration to pyronaridine (410 nmol/L), lower ID₅₀ to artemisinin (84.8 nmol/L) and lower resistant rate to piperaquine (7.1%). Of the 40 blood samples resistant to chloroquine, the cross resistance rate to pyronaridine was 52.5% (21/40), to artemisinin 37.5% (15/40) and to piperaquine 7.5% (3/40). Of the 3 blood samples resistant to piperaquine, all were cross-resistant to chloroquine (3/3), artemisinin (3/3) and pyronaridine (3/3). Among the samples displaying cross-resistance, 21 cases showed cross-resistance of chloroquine-pyronaridine, 15 of chloroquine-artemisinin, while 13 were artemisinin-pyronaridine cross-resistant, and respective 3 cases of piperaquine-resistance being cross-reactive with chloroquine, artemisinin and pyronaridine. Spearman rank correlation coefficient test revealed a significant correlation between artemisinin resistance and piperaquine or pyronaridine resistance (r = 0.354, 0.446; P < 0.05). The Pfcrt gene of 37 cases was sequenced and examined, indicative of triple-mutant genotype C₇₂V₇₃I₇₄E₇₅T₇₆ (mutation rate 100%, 37/37) at the loci 74-76. The mutation prevalence of Pfmdr gene at position N86Y and D1246Y were 2.1% (1/47) and 100% (49/49), respectively. The PfK13 gene was successfully sequenced from 20 isolates, and found to harbor 3 different mutations, including 10 cases with mutation at F446I, showing higher prevalence(50.0%, 10/20), one case with mutation at L492L/S and one case at C580Y showing low prevalence (5.0%, 1/20; 5.0%, 1/20; respectively). Among the drug resistant cases determined by in vitro drug test, the mutant prevalence of Pfcrt C₇₂V₇₃I₇₄E₇₅T₇₆, Pfmdr N₈₆Y₁₂₄₆, PfK13 I₄₄₆S₄₉₂C₅₈₀ and Pfcrt/Pfmdr I₇₄E₇₅T₇₆/Y₁₂₄₆ was 100% (37/37), 93.9% (46/49), 50% (10/20) and 69.0% (29/42) respectively. Spearman’s rank correlation coefficient analysis showed that there was no correlation of Pfcrt, Pfmdr and PfK13 gene mutation with the drug sensitivity in vitro. Conclusion The P. falciparum isolates from Laza City of China-Myanmar border region have developed resistance to chloroquine widely, and resistance to pyronaridine and artemisinin to certain extent, but remain usceptible to piperaquine.

Key words: Plasmodium falciparum, Drug sensitivity, In vitro microtest, Resistant gene, Laza City of Myanmar

CLC Number:

R382.312

ZHANG Cang-lin, NIE Ren-hua, XU Dan, LV Gao-wei, WANG Jian, YANG Ya-ming, DENG Yan, LIU Yan, ZHOU Hong-ning. Correlation of Pfcrt, Pfmdr and PfK13 gene polymorphisms and in vitro drug susceptibility of Plasmodium falciparum isolates from China-Myanmar border region[J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2020, 38(5): 580-588.

Figures/Tables 6

Table 1

Table 2

Table 3

Fig. 1

Fig. 2

Table 4

The frequency distribution of different genotypes of Pfcrt, Pfmdr and PfK13 in in vitro drug susceptibility test of P. falciparum isolates from China-Myanmar Border Region in 2009

基因类型^a Genotype^a	血样数量 No. isolates	百分比/% Percentage/%	体外检测对各药物产生抗性的血样数 Cases of in vitro resistance to drugs
基因类型^a Genotype^a	血样数量 No. isolates	百分比/% Percentage/%	青蒿素 Artemisinin		氯喹 Chloroquine		哌喹 Piperaquine	咯萘啶 Pyronaridine
Pfcrt基因（体外,n = 35） Pfcrt gene (in vitro, n = 35)
三重基因突变C₇₂V₇₃I₇₄E₇₅T₇₆ Triple-mutant genotype C₇₂V₇₃I₇₄E₇₅T₇₆	37	100	12	28		3			16
Pfmdr基因（体外,86位点n = 45,1246位点n = 47） Pfmdr gene (in vitro, n = 45 at codon 86, n = 47 at codon 1246）
单基因突变Y₁₂₄₆ Single-mutant genotype Y₁₂₄₆	2	4.1	0		2		0	1
单基因突变N₈₆Y₁₂₄₆ Single-mutant genotype N₈₆Y₁₂₄₆	46	93.9	16		34		3	21
双重突变Y₈₆Y₁₂₄₆ Double-mutant genotype Y₈₆Y₁₂₄₆	1	2.0	0		1		0	0
PfK13基因（体外, n = 20） PfK13 gene (in vitro, n = 20)
野生型F₄₄₆S₄₉₂C₅₈₀ Wild-type genotype F₄₄₆S₄₉₂C₅₈₀	8	40.0	3		5		2	3
单基因突变I₄₄₆S₄₉₂C₅₈₀ Single-mutant genotype I₄₄₆S₄₉₂C₅₈₀	10	50.0	4		9		1	8
单基因突变F₄₄₆L/S₄₉₂C₅₈₀ Single-mutant genotype F₄₄₆L/S₄₉₂C₅₈₀	1	5.0	1		1		0	1
单基因突变F₄₄₆S₄₉₂Y₅₈₀ Single-mutant genotype F₄₄₆S₄₉₂Y₅₈₀	1	5.0	1		1		0	1
Pfcrt/Pfmdr 多基因突变I₇₄E₇₅T₇₆/Y₁₂₄₆ Pfcrt/Pfmdr multi-mutant genotypes I₇₄E₇₅T₇₆/Y₁₂₄₆	29	69.0	8		21		2	10
Pfcrt/Pfmdr多基因突变I₇₄E₇₅T₇₆/Y₈₆Y₁₂₄₆ Pfcrt/Pfmdr multi-mutant genotypes I₇₄E₇₅T₇₆/Y₈₆Y₁₂₄₆	1	2.4	0		1		0	0
Pfcrt/Pfmdr/PfK13多基因突变I₇₄E₇₅T₇₆/Y₁₂₄₆/I₄₄₆ Pfcrt/Pfmdr/PfK13 multi-mutant genotypes I₇₄E₇₅T₇₆/Y₁₂₄₆/I₄₄₆	6	14.3	3		5		1	5
Pfcrt/Pfmdr/PfK13多基因突变I₇₄E₇₅T₇₆/Y₁₂₄₆/L/S₄₉₂ Pfcrt/Pfmdr/PfK13 multi-mutant genotypes I₇₄E₇₅T₇₆/Y₁₂₄₆/L/S₄₉₂	1	2.4	1		1		0	1
Pfmdr/PfK13多基因突变Y₁₂₄₆/I₄₄₆ Pfmdr/PfK13 multi-mutant genotypes Y₁₂₄₆/I₄₄₆	4	9.5	1		4		0	3
Pfmdr/PfK13多基因突变Y₁₂₄₆/Y₅₈₀ Pfmdr/ PfK13 multi-mutant genotypes Y₁₂₄₆/Y₅₈₀	1	2.4	1		1		0	1

Table 4

References 45

[1]	WHO. WHO World Malaria Report 2019[R]. Geneva: WHO, 2019.
[2]	Guan YX, Tang LH. Molecular markers related to antimalarial resistance of Plasmodium falciparum and their applications on the surveillance to drug resistance[J]. Chin J Parasitol Parasit Dis, 2005,23(2):117-120. (in Chinese)
	( 官亚宜, 汤林华. 恶性疟原虫药物抗性相关的分子标记及其在药物抗性监测中的应用[J]. 中国寄生虫学与寄生虫病杂志, 2005,23(2):117-120.)
[3]	Harinasuta T, Suntharasamai P, Viravan C. Chloroquine-resistant falciparum malaria in Thailand[J]. Lancet, 1965,2(7414):657-660. doi: 10.1016/s0140-6736(65)90395-8 pmid: 4158213
[4]	Marsh K. Malaria disaster in Africa[J]. Lancet, 1998,352(9132):924.
[5]	Liu DQ, Cai XZ. The situation of sensitivity of Plasmodium falciparum to antimalarial drugs in China[J]. Chin J Parasitol Parasit Dis, 1996,14(1):37-41. (in Chinese)
	( 刘德全, 蔡贤铮. 我国恶性疟原虫对抗疟药敏感性的现状[J]. 中国寄生虫学与寄生虫病杂志, 1996,14(1):37-41.)
[6]	Che LG, Huang KG, Yang HL. The sensitivity of pyronaridine to chloroquine-resistant Plasmodium falciparum strain[J]. Chin J Parasitol Parasit Dis, 1984,2(4):280-280. (in Chinese)
	( 车立刚, 黄开国, 杨恒林. 抗氯喹恶性疟原虫株对咯萘啶敏感性的测定[J]. 中国寄生虫学与寄生虫病杂志, 1984,2(4):280-280.)
[7]	Liu GZ, Chen LG, Huang KG, et al. A suvery on the susceptibility of falciparum malaria to chloroquine in the desert sand area of Xinping county in Yunnan Province[J]. Chin J Parasitol Parasit Dis, 1983,1(4):6-7. (in Chinese)
	( 刘国志, 车立刚, 黄开国, 等. 云南新平县漠沙地区恶性疟对氯喹敏感性的调查[J]. 中国寄生虫学与寄生虫病杂志, 1983,1(4):6-7.)
[8]	Liu DQ, Feng XP, Yang HL, et al. Fluctuation in the resistance of Plasmodium falciparum to chloroquine in China[J]. Chin J Parasitol Parasit Dis, 2005,23(1):7-31. (in Chinese)
	( 刘德全, 冯晓平, 杨恒林, 等. 我国恶性疟原虫对氯喹抗性的消长[J]. 中国寄生虫学与寄生虫病杂志, 2005,23(1):7-31.)
[9]	Yang HL, Liu DQ, Dong Y, et al. The sensitivity of in vitro of Plasmodium falciparum to seven antimalarial drugs[J]. Chin J Parasitol Parasit Dis, 1995,13(2):111-113. (in Chinese)
	( 杨恒林, 刘德全, 董莹, 等. 体外测定恶性疟原虫对七种抗疟药的敏感性[J]. 中国寄生虫学与寄生虫病杂志, 1995,13(2):111-113.)
[10]	Yang YM, Yang HL, Dong Y, et al. The sensitivity of in vitro of Plasmodium falciparum to seven antimalarial drugs in China-Myanmar border areas[J]. J Practic Parasit Dis, 1994, ( 3):23-26. (in Chinese)
	( 杨亚明, 杨恒林, 董莹, 等. 中缅边境地区恶性疟原虫对7种抗疟药敏感性的体外测定[J]. 实用寄生虫病杂志, 1994, ( 3):23-26.)
[11]	Yang HL, Yang PF, Yang YM. The susceptibility of in vitro of Plasmodium falciparum to mefloquine, quinine, ampicolaquine, chloroquine, sulfadioxine/pyrimethamine and clonaphthalidine in southern Yunnan[J]. Chin J Parasitol Parasit Dis, 1994,12(2):140-142. (in Chinese)
	( 杨恒林, 杨品芳, 杨亚明. 云南南部恶性疟原虫对甲氟喹、奎宁、氨酚喹、氯喹、磺胺多辛/乙胺嘧啶及咯萘啶敏感性的体外测定[J]. 中国寄生虫学与寄生虫病杂志, 1994,12(2):140-142.)
[12]	Huang QL, Zhou QL, Wu Z, et al. A study on the sensitivity of Plasmodium falciparum to chloroquine, qupiperaquine, ampicolaquine, mefloquine and quinine in Hainan Province[J]. Chin J Parasitol Parasit Dis, 1988,6(s1):19. (in Chinese)
	( 黄祺林, 周洁娴, 伍柱, 等. 海南省恶性疟原虫对氯喹、喹哌、氨酚喹、甲氟喹及奎宁敏感性的继续观察[J]. 中国寄生虫学与寄生虫病杂志, 1988,6(s1):19.)
[13]	WHO. Guidelines for the treatment of malaria[S]. Geneva: WHO, 2006.
[14]	Song J, Jiang GF, Chen PQ, et al. Analysis of Pfcrt polymorphism of chloroquine-resistant gene of Plasmodium falciparum in Hainan Province[J]. Chin J Parasit Dis Control, 2005,18(3):175-177. (in Chinese)
	( 宋杰, 江钢锋, 陈沛泉, 等. 海南省恶性疟原虫氯喹抗性相关基因Pfcrt多态性分析[J]. 中国寄生虫病防治杂志, 2005,18(3):175-177.)
[15]	Babiker HA, Pringle SJ, Abdel-Muhsin A, et al. High-level chloroquine resistance in Sudanese isolates of Plasmodium falciparum is associated with mutations in the chloroquine resistance transporter gene Pfcrt and the multidrug resistance gene Pfmdr1[J]. J Infect Dis, 2001,183(10):1535-1538. doi: 10.1086/320195 pmid: 11319692
[16]	Djimde A, Doumbo OK, Cortese JF, et al. A molecular marker for chloroquine-resistant falciparum malaria[J]. N Engl J Med, 2001,344(4):257-263. doi: 10.1056/NEJM200101253440403 pmid: 11172152
[17]	Lakshmanan V, Bray PG, Verdier-Pinard D, et al. A critical role for PfCRT K76T in Plasmodium falciparum verapamil-reversible chloroquine resistance[J]. EMBO J, 24(13):2294-2305. doi: 10.1038/sj.emboj.7600681 pmid: 15944738
[18]	WHO. Status report on artemisinin resistance and ACT efficacy[R]. Geneva: WHO, 2018.
[19]	Imwong M, Suwannasin K, Kunasol C, et al. The spread of artemisinin-resistant Plasmodium falciparum in the Greater Mekong subregion: a molecular epidemiology observational study[J]. Lancet Infect Dis, 2017,17:491-497. doi: 10.1016/S1473-3099(17)30048-8 pmid: 28161569
[20]	Amato R, Lim P, Miotto O, Amaratunga C, et al. Genetic markers associated with dihydroartemisinin-piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype-phenotype association study[J]. Lancet Infect Dis, 2017,17:164-173. doi: 10.1016/S1473-3099(16)30409-1 pmid: 27818095
[21]	Witkowski B, Duru V, Khim N, et al. A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype-genotype association study[J]. Lancet Infect Dis, 2017,17:174-183. doi: 10.1016/S1473-3099(16)30415-7 pmid: 27818097
[22]	Liu DQ, Ren DX. A medium for the determination of resistance to Plasmodium falciparum in study site[J]. Chin J Parasitol Parasit Dis, 1989,7(2):112-114. (in Chinese)
	( 刘德全, 任道性. 一种便于现场测定恶性疟原虫抗药性的培养基[J]. 中国寄生虫学与寄生虫病杂志, 1989,7(2):112-114.)
[23]	Rieckmann KH, Campbell GH, Sax LJ, et al. Drug sensitivity of Plasmodium falciparum[J]. 1978,1(8054):22-23.
[24]	Lin SG, Liu DQ, Zhuo KR, et al. Determination of Plasmodium falciparum to antimalarials in Ledong County, Hainan Province[J]. J Trop Med, 2005,5(8):1707-1708. (in Chinese)
	( 林世干, 刘德全, 卓开仁, 等. 海南省乐东县恶性疟原虫对抗疟药的敏感性测定[J]. 中国热带医学, 2005,5(8):1707-1708.)
[25]	Zhang YL, Pan WQ. Research progress on artemisinin resistance in Plasmodium falciparum[J]. Chin J Parasitol Parasit Dis, 2015,33(6):418-424. (in Chinese)
	( 张逸龙, 潘卫庆. 恶性疟原虫对青蒿素产生抗性的研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2015,33(6):418-424.
[26]	Zhang CL, Zhou HN, Nie RH, et al. Species identification and sequence analysis of Plasmodium spp. in border areas of Yunnan Province by 18S rRNA-based nested PCR[J]. Chin J Parasitol Parasit Dis, 2016,34(3):220-226. (in Chinese)
	( 张苍林, 周红宁, 聂仁华, 等. 云南省边境地区疟原虫18S rRNA基因种类鉴定与序列分析[J]. 中国寄生虫学与寄生虫病杂志, 2016,34(3):220-226.)
[27]	Ariey F, Witkowski B, Amaratunga C, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria[J]. Nature, 2014,505(7481):50-55. doi: 10.1038/nature12876 pmid: 24352242
[28]	Zhang CL, Zhou HN, Wan J, et al. In vitro sensitivity of Plasmodium falciparum isolates from China-Myanmar border region to chloroquine, piperaquine and pyronaridine[J]. Chin J Parasitol Parasit Dis, 2012,30(1):41-44. (in Chinese)
	( 张苍林, 周红宁, 王剑, 等. 中缅边境地区恶性疟原虫对氯喹、哌喹、咯萘啶敏感性的体外测定[J]. 中国寄生虫学与寄生虫病杂志, 2012,30(1):41-44.)
[29]	Yang HL, Liu DQ, Yang YM, et al. In vitro sensitivity of Plasmodium falciparum to eight antimalarials in China-Myanmar and China-Lao PDR border areas[J]. Southeast Asian J Trop Med Public Health, 1997,28(3):460-464. pmid: 9561592
[30]	Yang HL, Yang PF, Li XL, et al. The change of Plasmodium falciparum resistance to chloroquine in Yunnan Province, China[J]. J Pathog Biol, 2005,18(5):368-370. (in Chinese)
	( 杨恒林, 杨品芳, 李兴亮, 等. 云南省恶性疟原虫对氯喹抗性的变化[J]. 中国病原生物学杂志, 2005,18(5):368-370.)
[31]	Witkowski B, Amaratunga C, Khim N, et al. Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in vitro and ex vivo drug-response studies[J]. Lancet Infect Dis, 2013,13(12):1043-1049. doi: 10.1016/S1473-3099(13)70252-4 pmid: 24035558
[32]	Andriantsoanirina V, Ratsimbasoa A, Bouchier C, et al. Chloroquine clinical failures in P. falciparum malaria are associated with mutant Pfmdr-1, not Pfcrt in Madagascar[J]. PLoS One, 2010,5(10):e13281. doi: 10.1371/journal.pone.0013281 pmid: 20967251
[33]	Flueck TP, Jelinek T, Kilian AH, et al. Correlation of in vivo-resistance to chloroquine and allelic polymorphisms in Plasmodium falciparum isolates from Uganda[J]. Trop Med Int Health, 2000,5(3):174-178. doi: 10.1046/j.1365-3156.2000.00543.x pmid: 10747279
[34]	Miotto O, Amato R, Ashley EA, et al. Genetic architecture of artemisinin-resistant Plasmodium falciparum[J]. Nat Genet, 2015,47(3):226-234. doi: 10.1038/ng.3189 pmid: 25599401
[35]	Huang F, Takala-Harrison S, Jacob CG, et al. A single mutation in K13 predominates in Southern China and is associated with delayed clearance of Plasmodium falciparum following artemisinin treatment[J]. J Infect Dis, 2015,212(10):1629-1635. doi: 10.1093/infdis/jiv249 pmid: 25910630
[36]	Zhang GQ, Guan GQ, Hu L, et al. The polymorphisms of Pfcrt 72-76 in Plasmodium falciparum isolated from China and their relationships with chloroquine resistance[J]. Chin J Zoono, 2009,25(8):725-728. (in Chinese)
	( 张国庆, 官亚宜, 胡铃, 等. 中国恶性疟原虫氯喹抗药性相关基因Pfcrt 72-76位点基因型分析[J]. 中国人兽共患病学报, 2009,25(8):725-728.)
[37]	Yang Z, Zhang Z, Sun X, et al. Molecular analysis of chloroquine resistance in Plasmodium falciparum in Yunnan Province, China[J]. Trop Med Int Health, 2007,12(9):1051-1060. doi: 10.1111/j.1365-3156.2007.01882.x pmid: 17875016
[38]	Hao M, Jia D, Li Q, et al. In vitro sensitivities of Plasmodium falciparum isolates from the China-Myanmar border to piperaquine and association with polymorphisms in candidate genes[J]. Antimicrob Agents Chemother, 2013,57(4):1723-1729. doi: 10.1128/AAC.02306-12 pmid: 23357760
[39]	Takahashi N, Tanabe K, Tsukahara T, et al. Large-scale survey for novel genotypes of Plasmodium falciparum chloroquine-resistance gene Pfcrt[J]. Malar J, 2012,11:92. doi: 10.1186/1475-2875-11-92 pmid: 22453078
[40]	Mbaisi A, Liyala P, Eyase F, et al. Drug susceptibility and genetic evaluation of Plasmodium falciparum isolates obtained in four distinct geographical regions of Kenya[J]. Antimicrob Agents Chemother, 2004,48(9):3598-3601. doi: 10.1128/AAC.48.9.3598-3601.2004 pmid: 15328137
[41]	Song J. Study of chloroquine-resistant gene Pfmdr1 polymorphisms of Plasmodium falciparum from Hainan Province[J]. J Trop Med, 2005,5(1):26-29. (in Chinese)
	( 宋杰. 海南省恶性疟原虫氯喹抗性相关基因 Pfmdr1多态性分析[J]. 热带医学杂志, 2005,5(1):26-29.)
[42]	Guan YY, Zhang GQ, Hu L, et al. Relationships between chloroquine resistance and polymorphisms in Pfcrt and Pfmdr1 in Plasmodium falciparum isolated from China[J]. J Pathog Biol, 2009,4(1):27-31. (in Chinese)
	( 官亚宜, 张国庆, 胡铃, 等. 我国恶性疟原虫Pfcrt和Pfmdr1基因多态性及与氯喹敏感性关系的研究[J]. 中国病原生物学杂志, 2009,4(1):27-31.)
[43]	Feng J, Zhou D, Lin Y, et al. Amplification of Pfmdr1, Pfcrt, Pvmdr1, and K13 propeller polymorphisms associated with Plasmodium falciparum and Plasmodium vivax isolates from the China-Myanmar border[J]. Antimicrob Agents Chemother, 2015,59(5):2554-2559. doi: 10.1128/AAC.04843-14 pmid: 25691632
[44]	Zhang J, Li N, Siddiqui FA, et al. In vitro susceptibility of Plasmodium falciparum isolates from the China-Myanmar border area to artemisinins and correlation with K13 mutations[J]. Int J Parasitol Drugs Drug Resist, 2019,10:20-27. doi: 10.1016/j.ijpddr.2019.04.002 pmid: 31009824
[45]	Gao Q, Tang LH, Fu LC, et al. WS/T 485-2016 The guidelines for the use of antimalarial drugs[S]. Beijing: National Health and Family Planning Commission, PRC, 2016. (in Chinese)
	( 高琪, 汤林华, 符林春, 等. WS/T 485-2016 抗疟药使用规范[S]. 北京: 中华人民共和国国家卫生和计划生育委员会, 2016.

基因Gene	引物Primer	引物序列（5′→3′） Primer sequence (5′→3′)	PCR轮次 PCR round	产物片段/bp Amplicon size/bp
Pfcrt	76A	GCGCGCGCATGGCTCACGTTTAGGTGGAG	第1轮	206
	76B	GGGCCCGGCGGATGTTACAAAACTATAGTTACC
	76D1	TGTGCTCATGTGTTTAAACTT	第2轮	145
	76D2	CAAAACTATAGTTACCAATTTTG
Pfmdr	86A	GCGCGCGTTGAACAAAAAGAGTACCGCTG	第1轮	450
	86B	GGGCCCTCGTACCAATTCCTGAACTCAC
	86D1	TTTACCGTTTAAATGTTTACCTGC	第2轮	291
	86D2	CCATCTTGATAAAAAACACTTCTT
	1246A	GGGGGATGACAAATTTTCAAGATTA	第1轮	295
	1246B	GGGGGACTAACACGTTTAACATCTT
	1246D1	AATGTAAATGAATTTTCAAACC	第2轮	203
	1246D2	CATCTTCTCTTCCAAATTTGATA
PfK13	PCR_F	CGGAGTGACCAAATCTGGGA	第1轮	2 181
	PCR_R	GGGAATCTGGTGGTAACAGC
	N1_F	GCCAAGCTGCCATTCATTTG	第2轮	849
	N1_R	GCCTTGTTGAAAGAAGCAGA

药物 Drug	测定血样 No. sample tested	抗性率/% Resistance rate/%	平均抑制浓度^a/nmol·L^-1 Mean inhibition concentration^a/nmol·L^-1	ID₅₀ （95%可信限） ID₅₀ (95%CI)	对其他抗疟药的抗性血样（交叉抗性率/%） No. resistance to other antimalarials (Proportion of cross resistance/%)
药物 Drug	测定血样 No. sample tested	抗性率/% Resistance rate/%		ID₅₀ （95%可信限） ID₅₀ (95%CI)	青蒿素 Artemisinin	氯喹 Chloroquine	哌喹 Piperaquine	咯萘啶 Pyronaridine
青蒿素 Artemisinin	42	40.5	640	84.8 (44.2~ 162.7)	-	15（88.2）	3（17.6）	13（76.5）
氯喹^[28] Chloroquine	42	95.2	880	320.5 (57.9~1775)	15（37.5）	-	3（7.5）	21（52.5）
哌喹^[28] Piperaquine	42	7.1	440	128.2 (125.1~ 131.4)	3（100）	3（100）	-	3（100）
咯萘啶^[28] Pyronaridine	42	54.8	410	96.0 (85.4~ 107.9)	13（56.5）	21（91.3）	3（13.0）	-